scPharmaceuticals Q2 2021 Earnings Report
Key Takeaways
scPharmaceuticals reported a net loss of $7.1 million for Q2 2021. They ended the quarter with $90.2 million in cash, cash equivalents, restricted cash and investments. The company is targeting FUROSCIX NDA resubmission in Q4.
Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX® NDA; no additional clinical data or device modifications required at this time.
Announced positive top-line results from the FREEDOM-HF study demonstrating that average 30-day heart failure-related costs were reduced by $17,753 per study subject in the FUROSCIX arm compared to historically matched comparators.
Ended Q2 with cash, cash equivalents, restricted cash and investments of $90.2 million, sufficient to fund operations, as currently planned, into 2023.
Lowered 2021 net loss guidance to $30.0 to $34.0 million.
scPharmaceuticals
scPharmaceuticals
Forward Guidance
The Company expects its net loss for 2021 to be in the range of $30.0 to $34.0 million for the fiscal year.